Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | SVP, Chief Scientific Officer | March 28, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date March 28, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 882,811 |
Reported balance
After 2026-03-28 transaction · row 1
1 source rowRow 1 · 2026-03-28 · Tax withholding · Disposed 3,924 · Balance 882,811 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy joint tenancy with Frances Chang and Sean Tucker | 51,465 |
Reported balance
Holding disclosure · report date 2026-03-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 51,465 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 9,060 |
Reported balance
Holding disclosure · report date 2026-03-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 9,060 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 9,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · nonDerivative · entry 2 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 9,060 F1 · price: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 45,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,640 F1 · price: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.